Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
119.93
Nov 06 • 3:59 PM ET Dollar change-4.18 Percentage change(-3.37%)
Aftermarket Close
120.00
Aftermarket • 7:30 PM ET Dollar change+0.07 Percentage change(0.06%)
Nov 05, 10:37 PMHaemonetics raises FY27 revenue and EPS guidance on strong plasma growth, trims margin outlook amid CSL ramp investments
Index
RUT
Market Cap
5.46B
Enterprise Value
6.32B
Income
103.91M
Sales
1.38B
Book/sh
19.74
Cash/sh
5.73
Employees
3009
IPO
May 10, 1991
P/E
53.66
Forward P/E
19.62
PEG
1.62
P/S
3.95
P/B
6.08
P/C
20.95
P/FCF
18.31
EV/EBITDA
17.30
EV/Sales
4.57
Quick Ratio
1.83
Current Ratio
2.84
Debt/Eq
1.25
LT Debt/Eq
1.24
Option/Short
Yes / Yes
EPS (ttm)
2.24
EPS next Y
6.11
EPS next Q
1.29
EPS this Y
7.46%
EPS next Y
14.67%
EPS next 5Y
12.08%
EPS past 3/5Y
-2.90% 5.81%
Sales past 3/5Y
4.51% 8.91%
EPS Y/Y TTM
-34.22%
Sales Y/Y TTM
4.11%
EPS Q/Q
22.79%
Sales Q/Q
9.30%
Insider Own
1.88%
Insider Trans
0.00%
Inst Own
107.99%
Inst Trans
3.41%
ROA
4.28%
ROE
11.89%
ROIC
5.16%
Gross Margin
56.63%
Oper. Margin
18.51%
Profit Margin
7.52%
SMA20
-0.14%
SMA50
7.59%
SMA200
50.07%
Trades
Shs Outstand
45.52M
Shs Float
44.64M
52W High
132.00 -9.14%
52W Low
51.00 135.16%
Volatility
5.03% 3.24%
ATR (14)
4.30
RSI (14)
55.48
Beta
0.57
Rel Volume
1.16
Avg Volume
719.54K
Volume
834,754
Perf Week
0.23%
Perf Month
0.39%
Perf Quarter
38.47%
Perf Half Y
117.58%
Perf YTD
49.63%
Perf Year
78.71%
Perf 3Y
35.58%
Perf 5Y
60.79%
Perf 10Y
250.16%
Prev Close
124.11
Price
119.93
Change %
-3.37%
Consensus
Buy
Avg. Price Target
$137.50
Implied Upside
+14.7%
Analysts10incl. previous ratings
Rating Distribution8 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 17, 2026Upgrade
C logoCCitigroup
Neutral → Buy$123+2.6%
May 22, 2026Upgrade
BAC logoBBofA Securities
Neutral → Buy$80-33.3%
May 12, 2026Reiterated
BBarrington Research
Outperform$94 → $89-25.8%
Dec 15, 2025Downgrade
NNeedham
Buy → Hold
Dec 11, 2025Downgrade
C logoCCitigroup
Buy → Neutral$88-26.6%
Aug 11, 2025Downgrade
RJF logoRRaymond James
Strong Buy → Outperform$78-35.0%
Aug 08, 2025Reiterated
BBarrington Research
Outperform$95 → $86-28.3%
Aug 08, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral$62-48.3%
Jul 09, 2025Upgrade
C logoCCitigroup
Neutral → Buy$90-25.0%
Jun 26, 2025Initiated
RRobert W. Baird
Outperform$87-27.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KROLL MARK WDirectorNov 10 '25Buy70.561,40098,78424,757Nov 12 04:18 PM
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
CEOMr. Christopher A. Simon
CFOMr. James C. D'Arecca CPA
Executive VP & COOMr. Frank W. Chan Ph.D.
J.D.Ms. Michelle L. Basil Esq.
Executive VP & Chief Commercial OfficerMr. Roy Galvin